Particle.news
Drug Development Weight Loss Drugs Clinical Trials Drug Safety Weight Loss Drug Pricing Drug Approval Prescription Drugs Vaccines Obesity Treatment Drug Regulation Drug Manufacturing Over-the-Counter Medications Medications Diabetes Treatment Medication Weight-Loss Drugs Drug Discovery Drug Shortages Diabetes Vaccine Development Obesity Treatments Pain Relief Weight Loss Medications Diabetes Medications Drug Research Prescription Medications GLP-1 Drugs Weight-loss Drugs Drug Approval Process Weight Loss Treatments Biotechnology Obesity Drugs Antiviral Drugs Opioids Pain Management Drug Sales Generic Drugs Drug Supply Chain Antibiotics Counterfeit Drugs Merck & Co. Diabetes Drugs Weight Management Drug Efficacy Opioid Crisis Antiviral Treatments FDA Regulations Drugs Painkillers Public Health Drug Side Effects Novo Nordisk Controlled Substances Obesity Drug Prices Eli Lilly FDA Cancer Treatment Drug Effectiveness Diabetes Medication Medication Safety Drug Supply Drug Trials Side Effects Benzodiazepines Product Safety OxyContin Drug Design Drug Regulations Alzheimer's Disease Advertising Drug Classes Medicines Weight-loss drugs Antibiotic Development Marine-Derived Compounds Diabetes drugs Drug Accessibility Weight-loss Medications Ozempic Drug Importation Medication Effects Drug Delivery Mental Health Dietary Supplements Drug Patents Abortion Medications Semaglutide Over-the-Counter Drugs Anti-Obesity Drugs Banned Substances FDA Approval Sedatives Biopharmaceuticals Diabetes Treatments Gene Therapy Regulation GLP-1 Agonists Injectable Drugs
The company warns of potential additional costs from pharmaceutical tariffs under investigation by the Trump administration, while advocating for tax policy reforms to support U.S. manufacturing.
